Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7119
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Walpole, I. | - |
dc.contributor.author | Lee, B. | - |
dc.contributor.author | Shapiro, J. | - |
dc.contributor.author | Thomson, B. | - |
dc.contributor.author | Lipton, L. | - |
dc.contributor.author | Ananda, S. | - |
dc.contributor.author | Usatoff, V. | - |
dc.contributor.author | McLachlan, S. A. | - |
dc.contributor.author | Knowles, B. | - |
dc.contributor.author | Fox, A. | - |
dc.contributor.author | Wong, R. | - |
dc.contributor.author | Cooray, P. | - |
dc.contributor.author | Burge, M. | - |
dc.contributor.author | Clarke, K. | - |
dc.contributor.author | Pattison, S. | - |
dc.contributor.author | Nikfarjam, M. | - |
dc.contributor.author | Tebbutt, N. | - |
dc.contributor.author | Harris, M. | - |
dc.contributor.author | Nagrial, Adnan M. | - |
dc.contributor.author | Zielinski, R. | - |
dc.contributor.author | Chee, C. E. | - |
dc.contributor.author | Gibbs, P. | - |
dc.date.accessioned | 2023-06-05T06:14:03Z | - |
dc.date.available | 2023-06-05T06:14:03Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Asia-Pacific Journal of Clinical Oncology 19(1):214-225, 2023 | - |
dc.identifier.uri | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7119 | - |
dc.description.abstract | BACKGROUND: Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resectable METHOD: A retrospective analysis of consecutive patients with localized PDAC between January 2016 and March 2019 within the Australasian Pancreatic Cancer Registry (PURPLE, Pancreatic cancer: Understanding Routine Practice and Lifting End results) was performed. Clinicopathological characteristics, treatment, and outcome were analyzed. Overall survival (OS) comparison was performed using log-rank model and Kaplan-Meier analysis. RESULTS: The PURPLE database included 754 cases with localised PDAC, including 148 (20%) cases with borderline resectable pancreatic cancer (BRPC). Of the 148 BRPC patients, 44 (30%) underwent immediate surgery, 80 (54%) received NA chemotherapy, and 24 (16%) were inoperable. The median age of NA therapy patients was 63 years and FOLFIRINOX (53%) was more often used as NA therapy than gemcitabine/nab-paclitaxel (31%). Patients who received FOLFIRINOX were younger than those who received gemcitabine/nab-paclitaxel (60 years vs. 67 years, p = .01). Surgery was performed in 54% (43 of 80) of BRPC patients receiving NA chemotherapy, with 53% (16 of 30) achieving R0 resections. BRPC patients undergoing surgery had a median OS of 30 months, and 38% (9 of 24) achieved R0 resection. NA chemotherapy patients had a median OS of 20 months, improving to 24 months versus 10 months for patients receiving FOLFIRINOX compared to gemcitabine/nab-paclitaxel (Hazard Ratio (HR) .3, p < .0001). CONCLUSIONS: NA chemotherapy use in BRPC is increasing in Australia. One half of patients receiving NA chemotherapy proceed to curative resection, with 53% achieving R0 resections. Patients receiving Infusional 5-flurouracil, Irinotecan and Oxaliplatin (FOLIRINOX) had increased survival than gemcitabine/nab-paclitaxel. Treatment strategies are being explored in the MASTERPLAN and DYNAMIC-Pancreas trials. | - |
dc.subject | Oncology | - |
dc.title | Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population | - |
dc.type | Journal Article | - |
dc.identifier.doi | https://dx.doi.org/10.1111/ajco.13807 | - |
dc.subject.keywords | Pancreatic Neoplasms | - |
dc.subject.keywords | Deoxycytidine | - |
dc.subject.keywords | Fluorouracil | - |
dc.subject.keywords | Carcinoma, Pancreatic Ductal | - |
dc.identifier.journaltitle | Asia-Pacific Journal of Clinical Oncology | - |
dc.identifier.department | Medical Oncology | - |
dc.contributor.wslhd | Nagrial, Adnan M. | - |
dc.type.studyortrial | Controlled Study | - |
dc.type.studyortrial | Major Clinical Study | - |
dc.type.studyortrial | Clinical Trial, Phase I | - |
dc.type.studyortrial | Clinical Trial, Phase III | - |
dc.type.studyortrial | Retrospective Study | - |
dc.identifier.pmid | 35831999 | - |
dc.identifier.facility | Westmead | - |
dc.identifier.facility | Blacktown | - |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.